Novo Nordisk Cuts Jobs: A Wegovy Strategy Shift

Novo Nordisk, the maker of Wegovy and Ozempic, slashes 9,000 jobs despite booming weight-loss drug market! Find out why the company is making this surprising move, how it plans to save $1.25 billion, and what it means for the future of obesity and diabetes research as competition with Eli Lilly heats up. Plus, discover how investors reacted to the news. Hosted on Acast. See acast.com/privacy for more information.